Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
28/07/2026 23:43
BRIEF-Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors July 28 (Reuters) - Nurexone Biologic Inc NRX.V:
CORPORATE UPDATES – NUREXONE APPOINTS MR. DAVID STOLICK TO THE BOARD OF DIRECTORS
Source text: ID:nGNX8FnBCT
Further company coverage: NRX.V
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement